Evidence map›Paper›PMID 42802119›Full record

ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2026

[Novel therapeutic strategies for liver metastases driven by the common microenvironment].

L X Shen, W J Fang, Z Tong

Abstract readReviewEnglish Abstract
In one paragraph

Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

L X ShenDepartment of Oncology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China.
W J FangDepartment of Oncology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China.
Z TongDepartment of Oncology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The liver is one of the most common target organs for distant metastasis from various malignant tumors. Once liver metastases develop, they often indicate a poor prognosis and may be accompanied with reduced therapeutic responses.Whether cancer cells originating from different primary sites can further colonize, survive, and form metastatic lesions after entering the liver is closely related to the liver's unique immune-tolerant state and alterations in vascular structures and metabolic microenvironment. Although different tumors have distinct tissue origins and molecular characteristics, they are often influenced by similar microenvironmental factors during intrahepatic progression and exhibit certain functional convergence. Based on this characteristic, different diseases treated with the same method aimed at liver cancer metastases possess certain theoretical and practical significance. Herein, the main characteristics of the liver's immune microenvironment are organized and discussed, with a focus on immunotherapy, anti-angiogenic therapy, and convergent therapy strategies involving emerging targets such as human epidermal growth factor receptor 2 and claudin-18.2, with the aim of providing a reference for the comprehensive treatment approaches for metastatic liver cancer.

Indexed as

Liver NeoplasmsTumor MicroenvironmentAngiogenesis InhibitorsHumansImmunotherapyLiverNeovascularization, PathologicAngiogenesis Inhibitors

Identifiers

PMID42802119
PMCPMC13616987

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.